News on sequencing-based testing, NGS gene panels, & diagnostic exomes in genetics, genomics, and molecular diagnostics.
The deal will open up more opportunities to study OmniSeq's 144-gene NGS test and Immune Report Card in real-world settings and as part of drug development trials.
Investigators studied 442 patients with CUP and found mutations that could inform a specific treatment decision in more than half of them.
The SPRING trial is exploring a three-drug strategy, starting with Ibrance, Inlyta, and Bavencio, and will validate a biomarker algorithm for predicting responders.
The researchers plan to work with the NIH's Genome Research Alliance for Transplantation consortium to compare their method with others.
The company reported $35.0 million in revenues, driven by higher adoption of its molecular information solutions.
The ancestors of the Arizona bark scorpion and other scorpions and spiders underwent whole-genome duplication, KJZZ reports.
A cryptographic approach could help researchers keep genomic data private while researchers analyze it, Scientific American reports.
Andy Page, the former president of 23andMe, has joined a diabetes-management startup, according to CNBC.
In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.
This webinar will present an in-depth look at how Memorial Sloan Kettering Cancer Center has developed and implemented a next-generation sequencing panel for mutational tumor profiling of advanced cancer patients.
This webinar will discuss the critical role that software can play for clinical labs looking to establish comprehensive genomic testing programs.